Anavex Life Sciences Corp (AVXL)

[falconer66a]

Others still in the barn....

And a3-71 five years down the road..

Well, Anavex 3-71 is an entirely new, distinct chapter in the Anavex playbook; yet to be revealed. Presently, almost everything on this message board discusses, pro or con, blarcamesine as an Alzheimer's therapy. Well and good; understandable with the recent release of clinical trial data. But looking at Anavex through a narrow tube (blarcamesine's confusing or incomplete Alzheimer's data) fails to a) consider the drug's other disease targets (such as Rett syndrome and Parkinson's disease dementia), or b) the phenomenal potentials of Anavex 3-71.

Very consequential is Anavex 3-71's ability, among many other things, to activate sigma-1 receptors at concentrations far lower than blarcamesine. Far less of that drug is required for therapeutic activity. I believe that it will eventually supplant blarcamesine and become Anavex's lead molecule.

Then, of course, there's Anavex 1-41 and Anavex 1066. Exactly how these proprietary molecules will play out therapeutically remains to be seen. Simply, Anavex Life Sciences Corp is not just blarcamesine against Alzheimer's. The company has a wide platform of new, unique, safe and efficacious sigma-1 receptor ligands of broad and diverse therapeutic applications. Anavex is not a one-horse show. The Anavex barn is loaded with multiple molecular steeds that in the next five years will transform 21st-century medicine.